Analysis of efficacy and safety of tacrolimus extended-release formulation on prevention of rejection and GVHD in allo-HSCT patients

Analysis of efficacy and safety of tacrolimus extended-release formulation on prevention of rejection and GVHD in allo-HSCT patients - Efficacy and safety of tacrolimus extended-ralease formulation

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000008004

Enrollment

Registered

2012-05-21

Start date

2012-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allo hematopoietic stem cell transplantations of hematopoietic disorders

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. patients who may switch to tacrolimus extended-release formulation from tacrolimus p.o after allo-HSCT 2. patients who gave written informed consent about this study

Exclusion criteria

Exclusion criteria: 1. patients who had allergic reaction to tacrolimus 2. patients with the administration ofcyclosporin A or bosentan 3. patients with the administration of potassium-conserving diuretic 4. patients who are pregnant or have the possiblity of pregnancy

Design outcomes

Primary

Measure	Time frame
Analysis of efficacy and safety of tacrolimus extended-release formulation on prevention of rejection and GVHD	—

Countries

Japan

Outcome results